Related Experiment Video
Updated: Jun 14, 2025
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
Published on: October 13, 2023
Three-dimensional dose prediction based on deep convolutional neural networks for brain cancer in CyberKnife:
Yuchao Miao1,2, Ruigang Ge3, Chuanbin Xie3
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Objectives:
Accurate beam modelling is essential for dose calculation in stereotactic radiation therapy (SRT), such as CyberKnife treatment. However, the present deep learning methods only involve patient anatomical images and delineated masks for training. These studies generally focus on traditional intensity-modulated radiation therapy (RT) plans. Nevertheless, this paper aims to develop a deep CNN-based method for CyberKnife plan dose prediction about brain cancer patients. It utilized modelled beam information, target delineation, and patient anatomical information.
Methods:
This study proposes a method that adds beam information to predict the dose distribution of CyberKnife in brain cases. A retrospective dataset of 88 brain and abdominal cancer patients treated with the Ray-tracing algorithm was performed. The datasets include patients' anatomical information (planning CT), binary masks for organs at risk (OARs) and targets, and clinical plans (containing beam information). The datasets were randomly split into 68, 6, and 14 brain cases for training, validation, and testing, respectively.
Results:
Our proposed method performs well in SRT dose prediction. First, for the gamma passing rates in brain cancer cases, with the 2 mm/2% criteria, we got 96.7% ± 2.9% for the body, 98.3% ± 3.0% for the planning target volume, and 100.0% ± 0.0% for the OARs with small volumes referring to the clinical plan dose. Secondly, the model predictions matched the clinical plan's dose-volume histograms reasonably well for those cases. The differences in key metrics at the target area were generally below 1.0 Gy (approximately a 3% difference relative to the prescription dose).
Conclusions:
The preliminary results for selected 14 brain cancer cases suggest that accurate 3-dimensional dose prediction for brain cancer in CyberKnife can be accomplished based on accurate beam modelling for homogeneous tumour tissue. More patients and other cancer sites are needed in a further study to validate the proposed method fully.
Advances In Knowledge:
With accurate beam modelling, the deep learning model can quickly generate the dose distribution for CyberKnife cases. This method accelerates the RT planning process, significantly improves its operational efficiency, and optimizes it.
